OVARIAN SEROUS ADENOCARCINOMA

This study is for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to standard platinum-based chemotherapy. It aims to see if taking two oral drugs, cediranib and olaparib, together works better than taking either drug alone or…

This early-phase trial is testing a new treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after standard therapy. Researchers are using a patient's own fat-derived stem cells to carry a specially engineered measles virus directly to the cancer…

This large study aimed to find out if giving a key chemotherapy drug (paclitaxel) once a week is better than giving it once every three weeks for treating advanced ovarian, fallopian tube, or primary peritoneal cancer. All participants also received another chemotherapy drug (car…

This large, late-stage trial is for people whose ovarian, fallopian tube, or primary peritoneal cancer has returned after initial successful treatment. It aims to find the best way to control the cancer by testing whether adding a drug called bevacizumab to standard chemotherapy,…

This study tested a combination of two drugs, cediranib and olaparib, for people with recurrent ovarian, fallopian tube, peritoneal, or triple-negative breast cancer. The goal was to see if using both drugs together is safe and works better than using olaparib alone to control th…